Carriers of the apolipoprotein E (APOE) ε4 allele, a genetic modifier, are at increased risk for the development of sporadic AD, manifest dementia symptoms earlier than ε4-negative persons with the disease, and exhibit accelerated conversion rates from MCI to AD [3]. The gene discussed is APOE; the disease is dementia.